Neurapheresis™ CSF Management System
Neurapheresis™ CSF Management System
Active CSF management system removes blood, and neurotoxins. The system removes more blood and at faster rate than competing therapies thereby reducing further complications.
Subarachnoid Hemorrhage
- 40,000 US cases/year
- High-acuity, High-cost condition
- 250 Tier 1 Stroke Centers (50+ SAH cases/year)
A Bigger Opportunity
Because the Neurapheresis™ system is actively clearing CSF, it offers the potential to treat more conditions.
ALS
- Toxins propagate via CSF
- 35,000 US pateints annually
MS
- CSF immunoglobulins drive damage
- 1M people in US living with MS, up to 50% of whom could benefit
Meningitis
- Organism and Inflammatory mediators build up in CSF
- An untreatable global problem
Other Conditions
- Leptomeningeal metastases, cryptococcal meningitis
- 5-10% of cancer patients (about 110,000 annually)
Current Problem
Inadequate Standard of Care
No CSF removal
Wait and see
Drains
Slow, passive drains
No filtration
Adjacent Tech
CNS drug delivery
Today’s standard of care is inadequate
The current standard treats the aneurysm, and fingers are crossed.
- Clipping or coiling only addresses the primary injury
- Average ICU stay is >14 days to monitor for secondary complications
- High morbidity and mortality rates
50% Morbidity
15% Mortality
Our solution: Neurapheresis™
The first therapeutic System for active CSF clearance and neuro-restoration.
- Closed loop, automated control
- Standard of care average ICU stay is >14 days while on the lookout monitor for secondary complications
- Multi-indication potential across CNS diseases
The longer toxins remain in the cSF, the greater risk
Neurapheresis significantly reduces blood and protein compared to EVDs and Lumbar Drains.
10-12 day acceleration in return to normal vs. standard of care.
Reduces inflammation, need for shunts, and long-term complications
RBCs in CSF
Proteins in CSF
Neurapheresis™ System in Action
- Rapid removal of blood and breakdown products from the CSF
- Minimally invasive approach provides early intervention that reduces morbidity
- Uses standard, familiar, lumbar access to deliver patented dual-lumen catheter
- Procedure start to initiation of therapy typically in less than 20 minutes
- Typical treatment times of 36 to 72 hours
- Contaminated CSF withdrawn in the lumbar region, returned to cervical spine
- Tangential flow filters maximize toxin removal while minimizing lysis
- Proprietary algorithms match filtration rate with physiologic CSF production